{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:59:28Z","timestamp":1783022368735,"version":"3.54.6"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1124\/dmd.117.075994","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T13:45:14Z","timestamp":1508420714000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Organic Anion\u2013Transporting Polypeptide (OATP)\u2013Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver"],"prefix":"10.1016","volume":"46","author":[{"given":"Masashi","family":"Uchida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriko","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Kakuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chise","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.075994_bib1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.114.056978","article-title":"Application of chimeric mice with humanized liver for study of human-specific drug metabolism","volume":"42","author":"Bateman","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/dmd.111.043489","article-title":"In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation","volume":"40","author":"Bi","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.114.057968","article-title":"Differential effects of rifampin and ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a\/b knockout mice","volume":"42","author":"Chang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.116.236935","article-title":"Disrupted murine gut-to-human liver signaling alters bile acid homeostasis in humanized mouse liver models","volume":"360","author":"Chow","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.075994_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/dmd.115.063347","article-title":"Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans","volume":"43","author":"Chu","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.075994_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.taap.2013.03.019","article-title":"ATP-dependent transport of statins by human and rat MRP2\/Mrp2","volume":"269","author":"Ellis","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.117.075994_bib8","unstructured":"European Medicines Agency, Committee for Human Medicinal Products (2012) Guideline on the Investigation of Drug Interactions [Internet]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf."},{"key":"10.1124\/dmd.117.075994_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11095-012-0918-y","article-title":"Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential","volume":"30","author":"Gertz","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.075994_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.117.075994_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/dmd.112.049312","article-title":"Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement","volume":"41","author":"Grime","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(02)00633-8","article-title":"The superfamily of organic anion transporting polypeptides","volume":"1609","author":"Hagenbuch","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.117.075994_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/dmd.111.042754","article-title":"Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver","volume":"40","author":"Hasegawa","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.117.075994_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib18","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1124\/dmd.113.051052","article-title":"in vivo in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor","volume":"41","author":"Imaoka","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/mol.112.081927","article-title":"Murine Oatp1a\/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure","volume":"83","author":"Iusuf","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.117.075994_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/00498254.2013.869375","article-title":"Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method","volume":"44","author":"Kadono","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ijms15010058","article-title":"in vivo in vitro enzyme induction studies","volume":"15","author":"Kakuni","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.117.075994_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.510300220","article-title":"Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2","volume":"30","author":"Kamisako","year":"1999","journal-title":"Hepatology"},{"key":"10.1124\/dmd.117.075994_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In vitro in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.075994_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2133\/dmpk.23.87","article-title":"Intestinal first-pass metabolism of CYP3A4 substrates","volume":"23","author":"Kato","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.075994_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03602530601021340","article-title":"Application of chimeric mice with humanized liver for predictive ADME","volume":"39","author":"Katoh","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.117.075994_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/00498250500296231","article-title":"In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver","volume":"35","author":"Katoh","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1124\/dmd.105.009076","article-title":"Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism","volume":"34","author":"Lau","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib30","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.117.075994_bib31","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","article-title":"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.117.075994_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00232-005-7004-x","article-title":"Organic anion transporting polypeptides of the OATP\/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode","volume":"208","author":"Meier-Abt","year":"2005","journal-title":"J Membr Biol"},{"key":"10.1124\/dmd.117.075994_bib33","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.112.046193","article-title":"Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes","volume":"40","author":"M\u00e9nochet","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/00498254.2016.1265160","article-title":"Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver","volume":"47","author":"Miyamoto","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/00498250500307251","article-title":"Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver","volume":"35","author":"Nishimura","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.114.057646","article-title":"Validation of uPA\/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS\/MS","volume":"42","author":"Ohtsuki","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/toxsci\/kfm041","article-title":"Humanization of excretory pathway in chimeric mice with humanized liver","volume":"97","author":"Okumura","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.117.075994_bib39","unstructured":"Pharmaceuticals and Medical Devices Agency (2014) Drug Interaction Guideline for Drug Development and Labeling Recommendations [Final Draft] [Internet]. Available from: https:\/\/www.solvobiotech.com\/documents\/Japanese_DDI_guideline_(draft)_2014Jan.pdf."},{"key":"10.1124\/dmd.117.075994_bib40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.114.057976","article-title":"Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins","volume":"42","author":"Salphati","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib42","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3109\/00498254.2012.689888","article-title":"Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers","volume":"42","author":"Samuelsson","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.111.040923","article-title":"in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver","volume":"40","author":"Sanoh","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1007112","article-title":"Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver","volume":"45","author":"Sanoh","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.075994_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.075994_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2017.02.042","article-title":"Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions","volume":"177","author":"Shitara","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1014264614637","article-title":"Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport","volume":"19","author":"Shitara","year":"2002","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.075994_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.117.075994_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib51","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1124\/dmd.113.052753","article-title":"in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys","volume":"41","author":"Takahashi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib52","doi-asserted-by":"crossref","first-page":"e0142145","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/dmd.117.075994_bib53","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near completely humanized liver in mice shows human-type metabolic responses to drugs","volume":"165","author":"Tateno","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.117.075994_bib54","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.075994_bib55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/clpt.1992.174","article-title":"Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients","volume":"52","author":"Turgeon","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib56","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2012) Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Draft Guidance [Internet]. Available from: https:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/981001gd.pdf."},{"key":"10.1124\/dmd.117.075994_bib57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.117.075994_bib58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jhep.2005.10.028","article-title":"Growth and differentiation of colony-forming human hepatocytes in vitro","volume":"44","author":"Yamasaki","year":"2006","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.117.075994_bib59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2133\/dmpk.DMPK-10-RG-047","article-title":"In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice","volume":"25","author":"Yamasaki","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.075994_bib60","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.037549","article-title":"Interaction of cytochrome P450 3A inhibitors with P-glycoprotein","volume":"303","author":"Yasuda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.075994_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2013.45","article-title":"ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans","volume":"94","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.075994_bib63","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624053984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.075994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:30:30Z","timestamp":1739903430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624053984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0090955624053984"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.075994","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organic Anion\u2013Transporting Polypeptide (OATP)\u2013Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.075994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}